High-Fat Diet Delays Liver Fibrosis Recovery and Promotes Hepatocarcinogenesis in Rat Liver Cirrhosis Model DOI Open Access
Daisuke Taguchi, Yohei Shirakami,

Hiroyasu Sakai

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(15), P. 2506 - 2506

Published: Aug. 1, 2024

More effective treatments for hepatitis viral infections have led to a reduction in the incidence of liver cirrhosis. A high-fat diet can lead chronic and fibrosis, but effects lipid intake on disease status, including C virus alcohol, after elimination cause are unclear. To investigate effects, we used rat cirrhosis model this study. Male Wistar rats were administered carbon tetrachloride 5 weeks. At 12 weeks age, one group was sacrificed. The remaining divided into four groups according whether or not they weeks, fed control diet. fibrosis became apparent then improved where discontinued, while it worsened continued. Liver notable both discontinuation continuation due administration In addition, precancerous lesions observed all groups, tumor size multiplicity higher diet-fed groups. expression genes related inflammation lipogenesis upregulated compared their controls. results suggest that worsens promotes carcinogenesis, presumably through enhanced lipogenesis, even eliminating underlying

Language: Английский

Associations between “Cancer Risk”, “Inflammation” and “Metabolic Syndrome”: A Scoping Review DOI Creative Commons
Elsa Vitale, Alessandro Rizzo, Kazuki Santa

et al.

Biology, Journal Year: 2024, Volume and Issue: 13(5), P. 352 - 352

Published: May 16, 2024

Individuals with metabolic syndrome exhibit simultaneously pro-thrombotic and pro-inflammatory conditions which more probably can lead to cardiovascular diseases progression, type 2 diabetes mellitus, some types of cancer. The present scoping review is aimed at highlighting the association between cancer risk, inflammation, syndrome.

Language: Английский

Citations

21
Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)? DOI Creative Commons
Mario Romeo, Marcello Dallio, Carmine Napolitano

et al.

Diagnostics, Journal Year: 2025, Volume and Issue: 15(3), P. 252 - 252

Published: Jan. 22, 2025

In recent years, novel findings have progressively and promisingly supported the potential role of Artificial intelligence (AI) in transforming management various neoplasms, including hepatocellular carcinoma (HCC). HCC represents most common primary liver cancer. Alarmingly, incidence is dramatically increasing worldwide due to simultaneous “pandemic” spreading metabolic dysfunction-associated steatotic disease (MASLD). MASLD currently constitutes leading cause chronic hepatic damage (steatosis steatohepatitis), fibrosis, cirrhosis, configuring a scenario where an onset has been reported even early stage. On other hand, serious plague, significantly burdening outcomes hepatitis B (HBV) C (HCV) virus-infected patients. Despite progress this cancer, overall prognosis for advanced-stage patients continues be poor, suggesting absolute need develop personalized healthcare strategies further. “cold war”, machine learning techniques neural networks are emerging as weapons, able identify patterns biomarkers that would normally escaped human observation. Using advanced algorithms, AI can analyze large volumes clinical data medical images (including routinely obtained ultrasound data) with elevated accuracy, facilitating diagnosis, improving performance predictive models, supporting multidisciplinary (oncologist, gastroenterologist, surgeon, radiologist) team opting best “tailored” individual treatment. Additionally, contribute enhancing effectiveness metabolomics–radiomics-based promoting identification specific HCC-pathogenetic molecules new targets realizing therapeutic regimens. era precision medicine, integrating into routine practice appears promising frontier, opening avenues cancer research

Language: Английский

Citations

3
Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches DOI Creative Commons
Tatjana Radosavljević,

Milica Branković,

Janko Samardžić

et al.

Antioxidants, Journal Year: 2024, Volume and Issue: 13(8), P. 906 - 906

Published: July 26, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty (NAFLD), encompasses a range of conditions from steatosis to steatohepatitis (NASH). Its prevalence, especially among patients with metabolic syndrome, highlights its growing global impact. The pathogenesis MASLD involves dysregulation, inflammation, oxidative stress, genetic factors and, notably, mitochondrial dysfunction. Recent studies underscore the critical role dysfunction in MASLD's progression. Therapeutically, enhancing function has gained interest, along lifestyle changes and pharmacological interventions targeting processes. FDA's approval resmetirom for metabolic-associated (MASH) fibrosis marks significant step. While represents progress, further research is essential understand MASLD-related fully. Innovative strategies like gene editing small-molecule modulators, alongside interventions, can potentially improve treatment. Drug repurposing new targets will advance therapy, addressing increasing burden. Therefore, this review aims provide better understanding identify more effective preventive treatment strategies.

Language: Английский

Citations

14
Risk and Prognosis of Hepatocellular Carcinoma in Mexican Americans with Type 2 Diabetes Mellitus DOI Creative Commons
Rikita Hatia,

Lu-Yu Hwang,

Ruosha Li

et al.

Journal of Hepatocellular Carcinoma, Journal Year: 2025, Volume and Issue: Volume 12, P. 93 - 106

Published: Jan. 1, 2025

Hepatocellular carcinoma (HCC) disproportionately affects Hispanic persons with higher age-specific incidence and increased mortality rates compared to non-Hispanic Whites. These high of may be explained by the variation in risk factors. Given prevalence type 2 diabetes mellitus (DM) among population, we aimed assess prognosis HCC Mexican Americans DM consideration treatment for DM. A case-control study 241 American patients 500 healthy controls Texas was conducted. Multivariable logistic regression analysis performed determine association between while adjusting other Also, a restricted conducted effects age at onset duration on risk. Interactions DM, heavy alcohol consumption, viral hepatitis infection were examined. Overall survival examined, multivariable Cox proportional hazards The adjusted odds ratio (AOR) 2.74 (P < 0.01). Compared who had 2-10 years, those it least 20 years an AOR 4.60 = 0.04). Metformin use associated reduced death cases hazard 0.72 0.01) as non-users. Our results demonstrate that independently Americans. improved Type significantly alone conjunction parameters metabolic syndrome population after

Language: Английский

Citations

1
Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights DOI Open Access
Ιωάννα Αγγελετοπούλου, Efthymios P. Tsounis, Christos Triantos

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(9), P. 4901 - 4901

Published: April 30, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent condition characterized by abnormal fat accumulation in the liver, often associated with metabolic disorders. Emerging evidence suggests a potential link between vitamin D deficiency and development progression of MASLD. The current review provides concise overview recent studies uncovering novel mechanistic insights into interplay Several epidemiological have highlighted significant association low levels increased risk Vitamin D, traditionally known for its role bone health, has now been recognized as key player various physiological processes, including immune regulation inflammation. Experimental using animal models demonstrated that exacerbates steatosis inflammation, suggesting protective against Mechanistically, appears to modulate MASLD through multiple pathways. Firstly, receptor (VDR) abundantly expressed cells, indicating direct regulatory hepatic function. Activation VDR shown suppress lipid providing basis observed effects. Additionally, influences insulin sensitivity, critical factor pathogenesis. Improved sensitivity may mitigate excessive thus attenuating progression. In parallel, exhibits anti-inflammatory properties inhibiting pro-inflammatory cytokines implicated pathophysiology. immunomodulatory effects extend reducing inflammation oxidative stress, drivers MASLD, likelihood hepatocyte injury fibrosis. Understanding complex exploring targeted therapeutic strategies preventive interventions. As modifiable factor, addressing this nutritional concern prove beneficial mitigating burden

Language: Английский

Citations

6
Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon DOI Open Access

Linda Galasso,

Lucia Cerrito, Valeria Maccauro

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 7191 - 7191

Published: June 29, 2024

Hepatocellular carcinoma (HCC) is the most frequent among primary liver tumors (90%) and one of main causes cancer-related death. It develops usually in a chronically inflamed environment, ranging from compensatory parenchymal regeneration to fibrosis cirrhosis: carcinogenesis can potentially happen each these stages. Inflammation determined by chronic viral infection (hepatitis B, hepatitis C, delta viruses) represents an important risk factor for HCC etiology through both direct damage immune-related mechanisms. The deregulation physiological immunological network lead carcinogenesis. recent introduction immunotherapy as gold-standard first-line treatment highlights role immune system inflammation double-edged weapon treatment. In this review we highlight how key hepatocarcinogenesis viral, alcohol metabolic diseases.

Language: Английский

Citations

6
Exploring Biomarkers in Nonalcoholic Fatty Liver Disease Among Individuals With Type 2 Diabetes Mellitus DOI
Fariba Ahmadizar, Zobair M. Younossi

Journal of Clinical Gastroenterology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Integrating biomarkers into a comprehensive strategy is crucial for precise patient management, especially considering the significant healthcare costs associated with diseases. Current studies emphasize urgent need paradigm shift in conceptualizing nonalcoholic fatty liver disease (NAFLD), now renamed metabolic dysfunction–associated steatotic (MASLD). Biomarkers are emerging as indispensable tools accurate diagnosis, risk stratification, and monitoring progression. This review classifies conventional novel categories, such lipids, insulin resistance, hepatic function, cutting-edge imaging/omics, evaluates their potential to transform approach MASLD among individuals type 2 diabetes mellitus (T2D). It focuses on critical role of early detection, enhancing predictive accuracy, discerning responses interventions (pharmacological or lifestyle modifications). Amid this discussion, complexities relationship between T2D explored, factors like age, gender, genetics, ethnicity, socioeconomic background. enhance effectiveness support global initiatives reduce burden MASLD, thereby improving public health outcomes. recognizes promising diagnostic precision while candidly addressing challenges implementing these advancements clinical practice. The transformative emerges central theme, reshape our understanding trajectories, prognosis, customization personalized therapeutic strategies improved From future perspective, identifying early-stage biomarkers, environmental impact through exposomes, applying multiomics may reveal additional insight development.

Language: Английский

Citations

5
Low-dose metformin suppresses hepatocellular carcinoma metastasis via the AMPK/JNK/IL-8 pathway DOI Creative Commons
Chengwen Zhao, Lu Zheng, Yuting Ma

et al.

International Journal of Immunopathology and Pharmacology, Journal Year: 2024, Volume and Issue: 38

Published: Jan. 1, 2024

Background and objectives Metformin, an oral hypoglycemic drug, has been suggested to possess antitumour activity in several types of cancers. Additionally, interleukin-8 (IL-8) reported be involved the development metastasis many However, effect metformin on IL-8 expression hepatocellular carcinoma (HCC) remains unclear. Therefore, this study aimed investigate whether could inhibit exert inhibitory HCC progression. Materials methods The levels were measured plasma 159 patients (86 men, 73 women; average age 56 years) culture supernatant cells (Hep3B HuH7) using flow cytometry. In addition, protein also validated by Human Protein Atlas (HPA) database. prognostic value was evaluated Kaplan–Meier Plotter association between immune checkpoints estimated TIMER Cancer Genome (TCGA) databases. What’s more, bioinformatics analysis, western blotting, transwell assays conducted illustrate molecular mechanism (≤1 mM) HCC. Results found increased patients, which is consistent with tissues. High significantly related poor prognosis. positively correlated Notably, we that low-dose secretion migration cells. Mechanistically, suppresses mainly through AMPK/JNK/IL-8/MMP9 pathway. Conclusion results indicate can suppressing expression. Targeting AMPK/JNK/IL-8 axis may a promising treatment strategy for metastasis.

Language: Английский

Citations

4
Metabolic syndrome traits differentially and cumulatively influence micro‐ and macrovascular disease risk in patients with MASLD DOI Creative Commons
Alex E. Henney, David R. Riley, Theresa Hydes

et al.

Liver International, Journal Year: 2024, Volume and Issue: 44(11), P. 3031 - 3049

Published: Sept. 2, 2024

Abstract Introduction The cumulative impact of metabolic syndrome (MetS) components on micro‐ and macrovascular disease in dysfunction‐associated steatotic liver (MASLD) is unclear. We aimed to determine whether the number MetS increases risk patients with MASLD. Methods performed a retrospective cohort study electronic medical records using TriNetX network, global federated database. exposure arm was hepatic steatosis (defined via International Classification Diseases, 10th Revision coding, or modified index), ≥1 (obesity/central adiposity, insulin resistance, hypertension, dyslipidaemia), compared reference adults without any steatosis. Our propensity score matched (1:1) for confounders 5 years follow‐up. Primary outcomes included microvascular (peripheral neuropathy, retinopathy, nephropathy) (cardiovascular events, cerebrovascular accidents, peripheral vascular disease) disease. Secondary analyses assessed additional these outcomes, as well sex. Results MASLD, defined by resistance ( n = 15 937), carried highest (HR 13.93 (95% CI 8.55–22.68)), whilst hypertension 53 028), (7.23 (6.45–8.13)). MASLD all greatest both (31.20 (28.88–33.70) 462 789)) (8.04 (7.33–8.82) 336 010)) Conclusion demonstrate differential effect multiple overall risk. most pronounced women. Aggressive factor management critical prevention complications.

Language: Английский

Citations

4
Recent advances in systemic therapies for unresectable hepatocellular carcinoma and their impact on clinical outcomes DOI Open Access
Kyoko Oura

Hepatology Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 3, 2025

Author declares no conflict of interests for this article.

Language: Английский

Citations

0